Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer, for the month of March 2019. The filing, dated March 28, 2019, serves to incorporate by reference a press release (Exhibit 99.1) issued on the same date. The registrant is incorporated in Belgium and files annual reports on Form 20-F. Note: The request metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document is a procedural filing designed to distribute a press release rather than a financial statement.
Material Changes
No material financial changes versus prior periods are detailed in the text of this Form 6-K. The filing focuses on the dissemination of the March 28, 2019, press release content.
Guidance, Outlook, and Risks
The filing incorporates a press release by reference but does not contain the text of that release within the body of the Form 6-K. Consequently, specific guidance, management commentary, risks, contingencies, or unusual items are not described in the provided text. The filing notes that quotes from Dr. John McHutchison and Dr. Walid Abi-Saab contained in the press release are excluded from incorporation by reference into certain registration statements.
Investor Verification Checklist
- Verify the content of the attached Exhibit 99.1 (Press Release dated March 28, 2019) for specific operational updates or clinical data.
- Confirm the registrant name is Galapagos NV and not Lakefront Biotherapeutics NV.
- Review the referenced Registration Statements (Forms F-3 and S-8) for the full context of the incorporated information.
- Check for subsequent filings if financial metrics are required, as this document contains none.